Cadila haelth care subsidiary Nesher Pharma gets USFDA nod to market ADHD tablets

Mumbai, November 04, 2017: Cadila Healthcare today said that Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from United States Food and Drug Administration (USFDA) to market Dextroamphetamine Sulfate and Amphetamine Sulfate tablets in the strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg, The drug will be produced at Nesher’s manufacturing facility at St
Louis, MO, USA. The tablets are used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy, Cadila said in a fillng with BSE.
The group now has over 165 approvals and so far filed more than 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process, filing added.

United News Of India